GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Comera Life Sciences Holdings Inc (OTCPK:CMRA) » Definitions » Beneish M-Score

Comera Life Sciences Holdings (Comera Life Sciences Holdings) Beneish M-Score : -6.21 (As of May. 23, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Comera Life Sciences Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -6.21 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Comera Life Sciences Holdings's Beneish M-Score or its related term are showing as below:

CMRA' s Beneish M-Score Range Over the Past 10 Years
Min: -6.5   Med: -6.36   Max: -6.21
Current: -6.21

During the past 3 years, the highest Beneish M-Score of Comera Life Sciences Holdings was -6.21. The lowest was -6.50. And the median was -6.36.


Comera Life Sciences Holdings Beneish M-Score Historical Data

The historical data trend for Comera Life Sciences Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Comera Life Sciences Holdings Beneish M-Score Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
Beneish M-Score
- - -

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - -6.50 -6.21

Competitive Comparison of Comera Life Sciences Holdings's Beneish M-Score

For the Biotechnology subindustry, Comera Life Sciences Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Comera Life Sciences Holdings's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Comera Life Sciences Holdings's Beneish M-Score falls into.



Comera Life Sciences Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Comera Life Sciences Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.1871+0.528 * 0.8683+0.404 * 1.6244+0.892 * 1.8182+0.115 * 0.5081
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.4842+4.679 * -0.817383-0.327 * 1.3082
=-6.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $0.10 Mil.
Revenue was 0.136 + 0.315 + 0.393 + 0.156 = $1.00 Mil.
Gross Profit was 0.094 + 0.259 + 0.276 + 0.106 = $0.74 Mil.
Total Current Assets was $2.63 Mil.
Total Assets was $3.07 Mil.
Property, Plant and Equipment(Net PPE) was $0.35 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.10 Mil.
Selling, General, & Admin. Expense(SGA) was $8.45 Mil.
Total Current Liabilities was $2.93 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -2.154 + -1.412 + -2.481 + -2.963 = $-9.01 Mil.
Non Operating Income was 0.009 + 0.073 + 0.027 + 0.054 = $0.16 Mil.
Cash Flow from Operations was -1.914 + -0.994 + -1.906 + -1.848 = $-6.66 Mil.
Total Receivables was $0.29 Mil.
Revenue was 0.235 + 0.147 + 0.095 + 0.073 = $0.55 Mil.
Gross Profit was 0.174 + 0.092 + 0.051 + 0.034 = $0.35 Mil.
Total Current Assets was $4.29 Mil.
Total Assets was $4.94 Mil.
Property, Plant and Equipment(Net PPE) was $0.56 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.07 Mil.
Selling, General, & Admin. Expense(SGA) was $9.60 Mil.
Total Current Liabilities was $3.43 Mil.
Long-Term Debt & Capital Lease Obligation was $0.17 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.1 / 1) / (0.294 / 0.55)
=0.1 / 0.534545
=0.1871

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.351 / 0.55) / (0.735 / 1)
=0.638182 / 0.735
=0.8683

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2.63 + 0.348) / 3.072) / (1 - (4.289 + 0.555) / 4.937)
=0.030599 / 0.018837
=1.6244

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1 / 0.55
=1.8182

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.071 / (0.071 + 0.555)) / (0.1 / (0.1 + 0.348))
=0.113419 / 0.223214
=0.5081

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(8.448 / 1) / (9.596 / 0.55)
=8.448 / 17.447273
=0.4842

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 2.932) / 3.072) / ((0.172 + 3.43) / 4.937)
=0.954427 / 0.729593
=1.3082

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-9.01 - 0.163 - -6.662) / 3.072
=-0.817383

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Comera Life Sciences Holdings has a M-score of -6.21 suggests that the company is unlikely to be a manipulator.


Comera Life Sciences Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Comera Life Sciences Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Comera Life Sciences Holdings (Comera Life Sciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
Executives
Michael Gerard Campbell officer: Chief Financial Officer C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Charles Cherington 10 percent owner ONE BOW STREET, CAMBRIDGE MA 02138
David Soane 10 percent owner C/O SOANE LABS, LLC, 380 NE 72ND TERRACE, MIAMI FL 33138
Robert Patrick Mahoney officer: Chief Scientific Officer 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Barbara K Finck director C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Kirsten Flowers director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
James Sherblom director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Stuart A Randle director 585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Sullivan Edward Aloysius Jr. director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Sirshendu Roopom Banerjee director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Janice Mccourt officer: Chief Business Officer C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Jeffrey S. Hackman director, officer: See Remarks 12 GILL STREET, SUITE 4650, WOBURN MA 01801
John D. Yee director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Neal Muni officer: See Remarks 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Phoenix Venture Partners Lp 10 percent owner 36 DOCKSIDE CIRCLE, REDWOOD SHORES CA 94065